Patients with both colorectal ACF and resectable polyps
Conditions
Interventions
receive 100mg aspirin and placebo for 8 weeks
receive 100mg aspirin and 250mg metformin for 8 weeks
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with resectable polyps. 2.Patients with more than 10 rectal ACF 3.Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1.Patients with lesion which preferred early resection. 2.History of regular use (defined as at least once per week) of NSAIDs and/or aspirin. 3.History of regular use of warfarin and/or DOAC. 4.History of diabetes mellitus (defined as more than HbA1c 6.5% or regular use of anti-diabetic drugs) . 5.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure 6.History of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer and inflammatory bowel disease 7.Pregnancy or possibility of pregnancy 8.Contraindication to aspirin or metformin 9.Allergy to aspirin or metformin 10.Patients judged as inappropriate candidates for the trial by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of change rectal ACF in aspirin plus placebo group and aspirin plus metformin group after 8weeks intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of rectal ACF before and after intervention in both group Ki67 labeling index of colorectal adnoema/cancer and normal mucosa before and after intervention Safety | — |
Countries
Japan
Contacts
Public ContactHigurashi Takuma
Yokohama City University Department of Gastroenterology and Hepatology
Outcome results
None listed